Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...
In this week’s View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results